NVCT
Nuvectis Pharma, Inc.
Industry
Biotechnology
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Loading...
Open
5.71
Mkt cap
96M
Volume
597K
High
5.73
P/E Ratio
-4.27
52-wk high
12.10
Low
4.83
Div yield
N/A
52-wk low
4.83

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.